Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeWages, Salaries and Other
Others
Ratios

Armata Pharmaceuticals (ARMP) Shares Outstanding (Diluted Average) (2016 - 2018)

Armata Pharmaceuticals (ARMP) has disclosed Shares Outstanding (Diluted Average) for 6 consecutive years, with $4.7 million as the latest value for Q3 2018.

  • Quarterly Shares Outstanding (Diluted Average) fell 15.69% to $4.7 million in Q3 2018 from the year-ago period, while the trailing twelve-month figure was $4.7 million through Sep 2018, down 15.69% year-over-year, with the annual reading at $6.6 million for FY2017, 568.21% up from the prior year.
  • Shares Outstanding (Diluted Average) hit $4.7 million in Q3 2018 for Armata Pharmaceuticals, roughly flat from $4.7 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $6.6 million in Q4 2017 to a low of $732578.0 in Q2 2016.
  • Historically, Shares Outstanding (Diluted Average) has averaged $4.6 million across 5 years, with a median of $5.3 million in 2015.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): crashed 94.18% in 2014 and later skyrocketed 653.49% in 2017.
  • Year by year, Shares Outstanding (Diluted Average) stood at $5.9 million in 2014, then fell by 8.08% to $5.4 million in 2015, then tumbled by 81.82% to $983846.0 in 2016, then skyrocketed by 568.21% to $6.6 million in 2017, then decreased by 29.23% to $4.7 million in 2018.
  • Business Quant data shows Shares Outstanding (Diluted Average) for ARMP at $4.7 million in Q3 2018, $4.7 million in Q2 2018, and $6.6 million in Q4 2017.